SynthesisInternational ophthalmology2026
Antimicrobial resistance in post-cataract endophthalmitis: a systematic review on resistance pattern and treatment outcomes.
Synthesis in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo systematically review the microbiological spectrum, antimicrobial resistance (AMR) patterns, management strategies, and outcomes in culture-positive endophthalmitis, a rare vision-threatening complication of cataract surgery increasingly challenged by resistance.
methodsA comprehensive literature search was conducted in PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials from 1 January 1990 to 30 June 2025. Eligible studies included culture-positive cases of acute Post-Cataract Endophthalmitis reporting antimicrobial susceptibility and outcomes. Data were extracted on organisms, resistance profiles, treatment strategies and visual acuity. Risk of bias was assessed using the ROBINS-I tool.
resultsSix studies (five retrospective, one prospective) from Europe, Asia, and North America met inclusion criteria. Coagulase-negative staphylococci predominated, with frequent methicillin and fluoroquinolone resistance; Staphylococcus, Streptococcus, and Pseudomonas were less common. An Indian cohort described multidrug-resistant Pseudomonas with near-universal resistance to fluoroquinolones, aminoglycosides, and cephalosporins but susceptibility to colistin, piperacillin, and imipenem. While vancomycin remained active against Gram-positive organisms, emerging resistance was reported in the United Kingdom. Visual outcomes varied: tap-and-inject was comparable to early pars plana vitrectomy (PPV), except in Gram-negative infections where PPV conferred benefit. Amikacin resistance correlated with poorer outcomes, whereas vancomycin or moxifloxacin resistance did not. Systemic antibiotics and intravitreal corticosteroids showed no consistent benefit.
conclusionAMR in Post-Cataract Endophthalmitis is an escalating concern with marked geographic variation. Prompt intravitreal therapy remains the key determinant of prognosis, but empiric regimens must reflect local resistance trends, particularly for Gram-negative coverage. Current evidence is limited by retrospective design and regional variability; multicentre prospective studies are needed to refine prophylaxis and treatment protocols, reducing visual and economic burden.
Indexed as
Identifiers
42498831What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.